ClinicalTrials.gg
CompletedNCT06062069Updated Oct 28, 2026Results posted

A Study of CT-868 in Type 1 Diabetes Mellitus

A Phase 2 interventional study of CT-868 and CT-868 Pen Injector in Overweight, Obese and Type 1 Diabetes Mellitus, sponsored by Carmot Therapeutics, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Overweight by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Overweight · Hoffmann-La Roche.

Enrollment
13th of 20
111 · median 326
Started
2023
with 2 others
Phase 2
7 of 20
1 open now
Registered
5th of 20
by date

Among the 20 studies in Overweight by Hoffmann-La Roche, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 7 in phase 2, and was the 5th registered.

Overweight

3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.

Browse Overweight studies →

Open to participants now

8 of the 20 studies in Overweight by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Overweight by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.

03

Conditions studied

  • Overweight
  • Obese
  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years of age or older at the time of signing
  • Have a documented clinical diagnosis of T1DM greater than or equal to 1 year before the Screening Visit
  • greater than or equal to27.0 kg/m2
  • (HbA1c) level between 7.0% and 10.0%, inclusive, at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Type 2 diabetes mellitus (T2DM) or any other types of diabetes, except T1DM
  • Experienced diabetic ketoacidosis (DKA) within 3 months prior to the Screening Visit
  • Experienced severe hypoglycemia (Level 3 as defined in the ADA Standards of Medical Care in Diabetes (ADA 2022) within 3 months prior to the Screening Visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    CT-868 Low Dose

    Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 1.8 mg, and it will be administered once daily for a total duration of 16 weeks.

    Drug: CT-868 · Device: CT-868 Pen Injector

  • Experimental
    CT-868 Medium Dose

    Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 4.1 mg, and it will be administered once daily for a total duration of 16 weeks.

    Drug: CT-868 · Device: CT-868 Pen Injector

  • Experimental
    CT-868 High Dose

    Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 6.6 mg, and it will be administered once daily for a total duration of 16 weeks.

    Drug: CT-868 · Device: CT-868 Pen Injector

  • Placebo comparator
    CT-868 Placebo

    Participants in this arm will receive a placebo designed to match the appearance and formulation of the drug CT-868. The intervention consists of a subcutaneous injection of this placebo. The placebo will be administered once daily for a duration of 16 weeks.

    Device: CT-868 Pen Injector · Drug: CT-868 Pen Injector, Placebo

Interventions

  • DrugCT-868

    CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.

    Also known as: Acmopatide, RO7795074

  • DeviceCT-868 Pen Injector

    The CT-868 pen injector is a multi-dose, single-participant, disposable pen.

  • DrugCT-868 Pen Injector, Placebo

    The placebo pen injector is identical and contains the same ingredients except for CT-868.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16

    Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the mixed-effect model of repeated measures (MMRM).

    Time frame: Baseline (Day 1) to Week 16

Secondary outcomes

  1. Percent Change From Baseline in Body Weight at Week 16

    Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.

    Time frame: Baseline (Day 1) to Week 16

  2. Change From Baseline in HbA1c (%) at Weeks 4, 8, and 12

    Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.

    Time frame: Baseline (Day 1) to Weeks 4, 8, and 12

  3. Percentage of Participants Achieving HbA1c Target of <7.0% at Week 16

    Percentages have been rounded off.

    Time frame: At Week 16

  4. Percentage of Participants Achieving HbA1c Target of ≤6.5% at Week 16

    Percentages have been rounded off.

    Time frame: At Week 16

  5. Percentage of Participants Achieving HbA1c Target of <5.7% at Week 16

    Time frame: At Week 16

  6. Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16

    Baseline was defined as the median daily insulin dose (units per day \[units/day\]) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16. Total daily insulin dose was only calculated when daily bolus and daily basal are both present.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  7. Change From Baseline in Basal Insulin Dose at Weeks 8 and 16

    Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  8. Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16

    Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  9. Percent Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16

    Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  10. Percent Change From Baseline in Basal Insulin Dose at Weeks 8 and 16

    Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  11. Percent Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16

    Baseline bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  12. Percent Change From Baseline in Body Weight-adjusted Total Daily Insulin Dose at Weeks 8 and 16

    Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM. units/kg/day=units per kilograms per day.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  13. Percent Change From Baseline in Body Weight-adjusted Basal Insulin Dose at Weeks 8 and 16

    Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  14. Percent Change From Baseline in Body Weight-adjusted Bolus Insulin Dose at Weeks 8 and 16

    Baseline of bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  15. Change From Baseline in Continuous Glucose Monitoring (CGM) Intraday Mean Sensor Glucose

    All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\< 8.5% or ≥ 8.5%) + Methods of insulin administration (pump or multiple daily injection \[MDI\]) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  16. Change From Baseline in CGM Interday Mean Sensor Glucose

    All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  17. Change From Baseline in Percentage of Time Spent in Range (TIR) 70-180 mg/dL

    All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  18. Change From Baseline in Percentage of TIR 70-140 mg/dL

    All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-140 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  19. Change From Baseline in CGM Percent Time Spent in Level 1 Hypoglycemia (Time Below Target Range [TBTR, <54-70 mg/dL]) and Level 2 Hypoglycemia (Time Very Below Target Range [TVBTR <54 mg/dL])

    All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay below the target range of \<54-70 mg/dL and very below the target range of \<54 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  20. Change From Baseline in CGM Percent Time Spent in Level 1 Hyperglycemia (Time Above Target Range [TATR, >180-250 mg/dL]) and Level 2 Hyperglycemia (Time Very Above Target Range [TVATR >250 mg/dL])

    All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay TATR \>180-250 mg/dL and TVATR \>250 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

    Time frame: Baseline (Day 1), Weeks 8 and 16

  21. Event Rate With Sensor Glucose <70 mg/dL Lasting at Least 120 Minutes

    All participants used a CGM device for glucose monitoring throughout the treatment. Data is reported for event rate (number of events per person-year). Number of events with sensor glucose \<70 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≥70 mg/dL for ≥15 minutes) was assessed. Percentages have been rounded off.

    Time frame: Weeks 8 and 16

  22. Event Rate With Sensor Glucose >250 mg/dL Lasting at Least 120 Minutes

    All participants used a CGM device for glucose monitoring throughout the treatment. Data are reported for event rates. Event=sensor glucose \>250 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≤180 mg/dL for ≥15 minutes). Percentages have been rounded off.

    Time frame: Weeks 8 and 16

  23. Number of Participants With TIR 70-180 mg/dL With ≥5% Points Improvement From Baseline

    All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.

    Time frame: At Weeks 8 and 16

  24. Number of Participants With TIR 70-180 mg/dL With ≥10% Points Improvement From Baseline

    All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.

    Time frame: At Weeks 8 and 16

  25. Number of Participants With TIR 70-180 mg/dL for >70% of the 14-day Collection Interval Around the Week 8 Visit and the 14-day Interval Prior to the Week 16 Visit

    All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.

    Time frame: At Weeks 8 and 16

  26. Number of Participants With Time Below Range (TBR) <70 mg/dL for <4% of Each Day

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  27. Number of Participants With TBR <54 mg/dL for <1% of Each Day

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  28. Number of Participants With Time Above Range (TAR) >180 mg/dL for <25% of Each Day

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  29. Number of Participants With TAR >250 mg/dL for <5% of Each Day

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  30. Number of Participants With TBR <70 mg/dL for <4% Over the 14-day Collection Window

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  31. Number of Participants With TBR <54 mg/dL for <1% Over the 14-day Collection Window

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  32. Number of Participants With TAR >180 mg/dL for <25% Over the 14-day Collection Window

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  33. Number of Participants With TAR >250 mg/dL for <5% Over the 14-day Collection Window

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  34. Percent Change From Baseline in the Glycemic Risk Index

    All participants used a CGM device for glucose monitoring throughout the treatment.

    Time frame: Baseline, Weeks 8 and 16

  35. Percent Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16

    Time frame: Baseline (Day 1), and Weeks 4, 8, 12, and 16

  36. Absolute Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16

    Time frame: Baseline (Day 1), and Weeks 4, 8, 12, and 16

  37. Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16

    Time frame: At Week 16

  38. Percentage of Participants Experiencing 1 or More Level 1, 2, or 3 Hypoglycemia Events (Worst Severity)

    Level 1 hypoglycemia: glucose between \<70-54 mg/dL; Level 2 hypoglycemia: glucose level between \<54 mg/dL; Level 3 hypoglycemia: These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma.

    Time frame: Postbaseline from Day 1 to Week 16

  39. Event Rate of Level 2 Hypoglycemia Over the 2-Week Baseline Period and the 16-Week Treatment Period

    The baseline period event rate was calculated as (the total number of events) / (14/365.25 \* number of patients). Baseline hypoglycemia events occurred within 14 days prior to first treatment start time (Day 1). The treatment period event rate was calculated as (the total number of events) / (sum of the person-time exposed to the study drug after randomization (in years)). Sum of the person-time exposed to the study drug after randomization is calculated as the time from first to last dose of study drug for all participants in the respective treatment arm.

    Time frame: Baseline Period (14 days before Day 1) and Treatment Period (up to 16 weeks)

  40. Number of Participants With Diabetic Ketoacidosis (DKA) Events

    DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 milliequivalents per liter \[mEq/L\]), and accompanied by symptoms/signs per the anti-drug antibody (ADA) consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.

    Time frame: Up to Week 18

  41. Participants With DKA Events That Led to Hospitalization or Emergency Room Visits During the Study

    DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 mEq/L), and accompanied by symptoms/signs per the ADA consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.

    Time frame: Up to Week 18

  42. Number of Participants With Adverse Events (AEs) and Adverse Device Effects (ADEs) Over the Period of 16 Weeks

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An ADE was defined as an AE related to the medical device; in this study, the medical device is the pen device with which the study drug is administered. This included any event that was the result of incomplete user manual information or of incorrect use of the medical device.

    Time frame: Up to 16 weeks

  43. Plasma Drug Concentrations of CT-868 at the Weeks 2, 4, 6, 8, 12, and 16 Visits

    Time frame: At 24 hours post-dose on Weeks 2, 4, 6, 8, 12, and 16

07

Results

Posted Oct 28, 2026

Participant flow

A total of 111 overweight and obese adult participants with type 1 diabetes mellitus (T1DM) took part in the study from 27 November 2023 to 07 July 2025 across 22 sites in the United States.

Participant flow — Overall Study
MilestoneArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Started29272827
Safety population29303418
Completed22232425
Not completed7442
Withdrew: Withdrawal by subject1200
Withdrew: Lost to follow-up2120
Withdrew: Reason not specified2122
Withdrew: Adverse event2000

Outcome measures

PrimaryChange From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16

Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the mixed-effect model of repeated measures (MMRM).

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Least squares mean · percentage
Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16
percentageArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16-0.25 ± 0.101-0.43 ± 0.105-0.59 ± 0.101-0.45 ± 0.104
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.223 · Difference in least square means: -0.18 · 90% CI -0.42 to 0.06
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.020 · Difference in least square means: -0.34 · 90% CI -0.57 to -0.10
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.161 · Difference in least square means: -0.20 · 90% CI -0.44 to 0.04
SecondaryPercent Change From Baseline in Body Weight at Week 16

Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.

Time frame:
Baseline (Day 1) to Week 16
Reported as:
Least squares mean · percentage change
Percent Change From Baseline in Body Weight at Week 16
percentage changeArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percent Change From Baseline in Body Weight at Week 160.29 ± 0.839-3.26 ± 0.865-6.43 ± 0.838-6.67 ± 0.861
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = <0.01 · Difference in least square means: -3.55 · 90% CI -5.45 to -1.65
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.01 · Difference in least square means: -6.72 · 90% CI -8.59 to -4.85
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.01 · Difference in least square means: -6.96 · 90% CI -8.85 to -5.06
SecondaryChange From Baseline in HbA1c (%) at Weeks 4, 8, and 12

Baseline was defined as the last available non-missing value prior to the first dose of the randomized study drug. The analysis was based on the MMRM.

Time frame:
Baseline (Day 1) to Weeks 4, 8, and 12
Reported as:
Least squares mean · percentage
Change From Baseline in HbA1c (%) at Weeks 4, 8, and 12
percentageArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 4-0.08 ± 0.067-0.17 ± 0.069-0.30 ± 0.068-0.20 ± 0.070
Change at Week 8-0.17 ± 0.087-0.35 ± 0.091-0.46 ± 0.086-0.24 ± 0.090
Change at Week 12-0.27 ± 0.099-0.36 ± 0.103-0.52 ± 0.098-0.35 ± 0.102
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.328 · Difference in least square means: -0.09 · 90% CI -0.25 to 0.06
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.021 · Difference in least square means: -0.22 · 90% CI -0.38 to -0.06
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.205 · Difference in least square means: -0.12 · 90% CI -0.28 to 0.04
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.137 · Difference in least square means: -0.19 · 90% CI -0.39 to 0.02
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.015 · Difference in least square means: -0.30 · 90% CI -0.50 to -0.10
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.552 · Difference in least square means: -0.07 · 90% CI -0.28 to 0.13
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.508 · Difference in least square means: -0.09 · 90% CI -0.33 to 0.14
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.069 · Difference in least square means: -0.25 · 90% CI -0.48 to -0.02
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.558 · Difference in least square means: -0.08 · 90% CI -0.32 to 0.15
SecondaryPercentage of Participants Achieving HbA1c Target of <7.0% at Week 16

Percentages have been rounded off.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Target of <7.0% at Week 16
percentage of participantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percentage of Participants Achieving HbA1c Target of <7.0% at Week 1636.445.066.740.9
SecondaryPercentage of Participants Achieving HbA1c Target of ≤6.5% at Week 16

Percentages have been rounded off.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Target of ≤6.5% at Week 16
percentage of participantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percentage of Participants Achieving HbA1c Target of ≤6.5% at Week 169.120.033.327.3
SecondaryPercentage of Participants Achieving HbA1c Target of <5.7% at Week 16
Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Target of <5.7% at Week 16
percentage of participantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percentage of Participants Achieving HbA1c Target of <5.7% at Week 160000
SecondaryChange From Baseline in Total Daily Insulin Dose at Weeks 8 and 16

Baseline was defined as the median daily insulin dose (units per day \[units/day\]) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16. Total daily insulin dose was only calculated when daily bolus and daily basal are both present.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Median · units/day
Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16
units/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline82.40 (27.9 to 113.1)68.80 (24.1 to 225.0)56.00 (4.0 to 166.2)59.00 (29.5 to 109.5)
Change at Week 8-3.00 (-73.0 to 16.8)-6.35 (-30.0 to 25.3)-18.00 (-74.0 to 7.0)-12.39 (-47.8 to 17.8)
Change at Week 16-4.50 (-73.0 to 50.5)-5.80 (-75.0 to 34.5)-9.33 (-36.4 to 25.4)-15.00 (-49.9 to 20.1)
SecondaryChange From Baseline in Basal Insulin Dose at Weeks 8 and 16

Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Median · units/day
Change From Baseline in Basal Insulin Dose at Weeks 8 and 16
units/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline34.4 (18.5 to 80.0)35.0 (16.1 to 110.0)37.0 (0.0 to 160.0)33.8 (16.0 to 69.5)
Change at Week 80.0 (-14.1 to 11.4)-0.9 (-10.2 to 5.8)-2.8 (-24.0 to 5.7)-3.7 (-16.9 to 6.7)
Change at Week 160.0 (-13.0 to 10.0)0.0 (-14.5 to 6.0)-0.5 (-13.0 to 12.0)-2.0 (-21.7 to 7.7)
SecondaryChange From Baseline in Bolus Insulin Dose at Weeks 8 and 16

Baseline was defined as the median daily insulin dose (units/day) over a consecutive 7-day period prior to Day 1, provided that at least 4 of those 7 days had non-missing daily insulin dose data. If no such 7-day period existed within the 14-day placebo run-in period, the baseline was considered missing. The same algorithm was used for calculating values for Week 8 and 16.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Median · units/day
Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16
units/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline32.80 (9.2 to 81.0)30.79 (6.0 to 115.0)26.45 (4.0 to 102.5)25.00 (5.0 to 66.0)
Change at Week 8-1.75 (-62.0 to 31.9)-2.91 (-25.5 to 19.5)-10.15 (-60.9 to 7.0)-8.09 (-33.0 to 12.2)
Change at Week 16-5.00 (-63.8 to 52.0)-7.08 (-70.0 to 34.5)-7.80 (-30.0 to 27.0)-6.20 (-36.0 to 9.8)
SecondaryPercent Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16

Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percentage change in units/day
Percent Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16
Percentage change in units/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percent Change at Week 8-8.32 ± 7.653-2.33 ± 8.792-24.25 ± 9.119-21.84 ± 8.121
Percent Change at Week 16-6.40 ± 8.1900.65 ± 9.404-9.75 ± 9.705-21.32 ± 8.597
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.446 · Difference in least square means: 5.99 · 95% CI -9.61 to 21.59
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.055 · Difference in least square means: -15.93 · 95% CI -32.24 to 0.37
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.079 · Difference in least square means: -13.52 · 95% CI -28.66 to 1.61
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.435 · Difference in least square means: 7.05 · 95% CI -10.91 to 25.01
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.719 · Difference in least square means: -3.35 · 95% CI -21.94 to 15.24
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.088 · Difference in least square means: -14.92 · 95% CI -32.13 to 2.28
SecondaryPercent Change From Baseline in Basal Insulin Dose at Weeks 8 and 16

Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percentage change in units/day
Percent Change From Baseline in Basal Insulin Dose at Weeks 8 and 16
Percentage change in units/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percent Change at Week 84.12 ± 4.8493.12 ± 5.155-3.39 ± 5.395-7.69 ± 5.056
Percent Change at Week 165.28 ± 5.2787.26 ± 5.8546.62 ± 6.011-4.45 ± 5.454
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.851 · Difference in least square means: -1.00 · 95% CI -11.59 to 9.59
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.185 · Difference in least square means: -7.51 · 95% CI -18.68 to 3.67
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.029 · Difference in least square means: -11.81 · 95% CI -22.36 to -1.26
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.753 · Difference in least square means: 1.99 · 95% CI -10.58 to 14.55
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.837 · Difference in least square means: 1.34 · 95% CI -11.63 to 14.31
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.113 · Difference in least square means: -9.73 · 95% CI -21.80 to 2.35
SecondaryPercent Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16

Baseline bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percentage change in units/day
Percent Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16
Percentage change in units/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percent Change at Week 8-10.55 ± 14.4890.15 ± 16.410-27.48 ± 16.847-34.96 ± 15.410
Percent Change at Week 16-15.86 ± 15.6180.72 ± 17.670-8.40 ± 18.100-31.43 ± 16.481
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.432 · Difference in least square means: 10.70 · 95% CI -16.25 to 37.64
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.231 · Difference in least square means: -16.93 · 95% CI -44.84 to 10.98
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.073 · Difference in least square means: -24.42 · 95% CI -51.20 to 2.37
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.308 · Difference in least square means: 16.59 · 95% CI -15.66 to 48.83
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.654 · Difference in least square means: 7.46 · 95% CI -25.68 to 40.60
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.328 · Difference in least square means: -15.57 · 95% CI -47.17 to 16.03
SecondaryPercent Change From Baseline in Body Weight-adjusted Total Daily Insulin Dose at Weeks 8 and 16

Baseline total daily insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM. units/kg/day=units per kilograms per day.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percent change in units/kg/day
Percent Change From Baseline in Body Weight-adjusted Total Daily Insulin Dose at Weeks 8 and 16
Percent change in units/kg/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percent Change at Week 8-9.02 ± 7.523-2.30 ± 8.674-20.39 ± 8.947-20.04 ± 8.022
Percent Change at Week 16-7.88 ± 7.8790.23 ± 9.119-4.04 ± 9.354-17.40 ± 8.343
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.389 · Difference in least square means: 6.72 · 95% CI -8.77 to 22.22
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.164 · Difference in least square means: -11.37 · 95% CI -27.52 to 4.78
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.147 · Difference in least square means: -11.02 · 95% CI -26.01 to 3.97
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.348 · Difference in least square means: 8.11 · 95% CI -9.06 to 25.28
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.666 · Difference in least square means: 3.84 · 95% CI -13.89 to 21.57
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.250 · Difference in least square means: -9.52 · 95% CI -25.92 to 6.88
SecondaryPercent Change From Baseline in Body Weight-adjusted Basal Insulin Dose at Weeks 8 and 16

Baseline basal insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percent change in units/kg/day
Percent Change From Baseline in Body Weight-adjusted Basal Insulin Dose at Weeks 8 and 16
Percent change in units/kg/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percent Change at Week 86.59 ± 4.9299.05 ± 5.2875.45 ± 5.639-1.27 ± 5.152
Percent Change at Week 166.80 ± 5.32813.00 ± 5.95716.81 ± 6.1964.49 ± 5.520
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.649 · Difference in least square means: 2.46 · 95% CI -8.28 to 13.20
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.843 · Difference in least square means: -1.14 · 95% CI -12.58 to 10.30
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.146 · Difference in least square means: -7.86 · 95% CI -18.53 to 2.81
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.331 · Difference in least square means: 6.20 · 95% CI -6.44 to 18.84
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.132 · Difference in least square means: 10.02 · 95% CI -3.09 to 23.12
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.705 · Difference in least square means: -2.30 · 95% CI -14.41 to 9.81
SecondaryPercent Change From Baseline in Body Weight-adjusted Bolus Insulin Dose at Weeks 8 and 16

Baseline of bolus insulin dose was defined as the median daily insulin dose over 7 days within a 14 consecutive days period prior to Day 1, provided that at least 4 out of those 7 days had non-missing daily insulin dose data. The similar algorithm applies to Week 8 and 16. The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percent change in units/kg/day
Percent Change From Baseline in Body Weight-adjusted Bolus Insulin Dose at Weeks 8 and 16
Percent change in units/kg/dayArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 8-12.10 ± 14.705-0.73 ± 16.650-24.83 ± 17.098-33.52 ± 15.704
Change at Week 16-17.86 ± 15.772-0.51 ± 17.860-3.73 ± 18.294-27.89 ± 16.713
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.412 · Difference in least square means: 11.37 · 95% CI -16.09 to 38.83
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.375 · Difference in least square means: -12.73 · 95% CI -41.16 to 15.69
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.122 · Difference in least square means: -21.42 · 95% CI -48.69 to 5.86
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.290 · Difference in least square means: 17.36 · 95% CI -15.19 to 49.90
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.401 · Difference in least square means: 14.13 · 95% CI -19.30 to 47.56
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.531 · Difference in least square means: -10.03 · 95% CI -41.89 to 21.84
SecondaryChange From Baseline in Continuous Glucose Monitoring (CGM) Intraday Mean Sensor Glucose

All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\< 8.5% or ≥ 8.5%) + Methods of insulin administration (pump or multiple daily injection \[MDI\]) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Continuous Glucose Monitoring (CGM) Intraday Mean Sensor Glucose
milligrams per deciliter (mg/dL)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 8-7.8 ± 6.47-9.7 ± 6.77-13.2 ± 6.452.5 ± 6.32
Change at Week 16-0.3 ± 6.43-8.6 ± 6.76-7.2 ± 6.74-5.5 ± 6.33
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.771 · Difference in least square means: -1.8 · 95% CI -14.4 to 10.7
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.379 · Difference in least square means: -5.4 · 95% CI -17.6 to 6.8
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.086 · Difference in least square means: 10.3 · 95% CI -1.5 to 22.2
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.189 · Difference in least square means: -8.3 · 95% CI -20.8 to 4.2
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.280 · Difference in least square means: -6.9 · 95% CI -19.4 to 5.7
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.390 · Difference in least square means: -5.2 · 95% CI -17.2 to 6.8
SecondaryChange From Baseline in CGM Interday Mean Sensor Glucose

All participants used a CGM device for glucose monitoring throughout the treatment. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · mg/dL
Change From Baseline in CGM Interday Mean Sensor Glucose
mg/dLArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 8-7.9 ± 6.38-9.5 ± 6.68-12.1 ± 6.342.4 ± 6.24
Change at Week 160.1 ± 6.33-8.8 ± 6.65-6.0 ± 6.63-5.1 ± 6.23
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.796 · Difference in least square means: -1.6 · 95% CI -14.0 to 10.8
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.480 · Difference in least square means: -4.3 · 95% CI -16.3 to 7.7
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.084 · Difference in least square means: 10.3 · 95% CI -1.4 to 22.0
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.152 · Difference in least square means: -8.9 · 95% CI -21.2 to 3.4
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.325 · Difference in least square means: -6.1 · 95% CI -18.5 to 6.2
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.379 · Difference in least square means: -5.2 · 95% CI -17.0 to 6.6
SecondaryChange From Baseline in Percentage of Time Spent in Range (TIR) 70-180 mg/dL

All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percentage of time
Change From Baseline in Percentage of Time Spent in Range (TIR) 70-180 mg/dL
Percentage of timeArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 84.4 ± 4.227.5 ± 4.418.3 ± 4.20-0.3 ± 4.14
Change at Week 16-0.3 ± 3.955.6 ± 4.153.7 ± 4.133.0 ± 3.90
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.467 · Difference in least square means: 3.1 · 95% CI -5.3 to 11.5
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.353 · Difference in least square means: 3.8 · 95% CI -4.3 to 12.0
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.235 · Difference in least square means: -4.8 · 95% CI -12.7 to 3.2
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.110 · Difference in least square means: 5.9 · 95% CI -1.4 to 13.2
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.279 · Difference in least square means: 4.0 · 95% CI -3.3 to 11.4
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.345 · Difference in least square means: 3.3 · 95% CI -3.7 to 10.3
SecondaryChange From Baseline in Percentage of TIR 70-140 mg/dL

All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-140 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percentage of time
Change From Baseline in Percentage of TIR 70-140 mg/dL
Percentage of timeArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 83.2 ± 3.745.1 ± 3.896.5 ± 3.69-2.3 ± 3.67
Change at Week 16-0.2 ± 3.534.6 ± 3.694.0 ± 3.701.6 ± 3.48
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.615 · Difference in least square means: 1.9 · 95% CI -5.6 to 9.4
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.368 · Difference in least square means: 3.3 · 95% CI -4.0 to 10.6
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.123 · Difference in least square means: -5.5 · 95% CI -12.6 to 1.5
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.155 · Difference in least square means: 4.8 · 95% CI -1.9 to 11.4
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.215 · Difference in least square means: 4.2 · 95% CI -2.5 to 10.9
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.571 · Difference in least square means: 1.8 · 95% CI -4.5 to 8.2
SecondaryChange From Baseline in CGM Percent Time Spent in Level 1 Hypoglycemia (Time Below Target Range [TBTR, <54-70 mg/dL]) and Level 2 Hypoglycemia (Time Very Below Target Range [TVBTR <54 mg/dL])

All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay below the target range of \<54-70 mg/dL and very below the target range of \<54 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · Percentage of time
Change From Baseline in CGM Percent Time Spent in Level 1 Hypoglycemia (Time Below Target Range [TBTR, <54-70 mg/dL]) and Level 2 Hypoglycemia (Time Very Below Target Range [TVBTR <54 mg/dL])
Percentage of timeArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
TBTR: Change at Week 80.3 ± 0.470.0 ± 0.500.1 ± 0.47-0.4 ± 0.46
TBTR: Change at Week 160.2 ± 0.46-0.1 ± 0.500.1 ± 0.500.1 ± 0.46
TVBTR: Change at Week 80.2 ± 0.180.0 ± 0.20-0.1 ± 0.18-0.1 ± 0.18
TVBTR: Change at Week 160.0 ± 0.310.3 ± 0.330.3 ± 0.350.5 ± 0.31
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.435 · Difference in least square means: -0.4 · 95% CI -1.3 to 0.6
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.609 · Difference in least square means: -0.2 · 95% CI -1.2 to 0.7
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.107 · Difference in least square means: -0.7 · 95% CI -1.6 to 0.2
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.613 · Difference in least square means: -0.2 · 95% CI -1.1 to 0.7
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.880 · Difference in least square means: -0.1 · 95% CI -1.0 to 0.9
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.872 · Difference in least square means: -0.1 · 95% CI -1.0 to 0.8
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.228 · Difference in least square means: -0.2 · 95% CI -0.6 to 0.1
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.096 · Difference in least square means: -0.3 · 95% CI -0.6 to 0.1
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.045 · Difference in least square means: -0.3 · 95% CI -0.7 to 0.0
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.364 · Difference in least square means: 0.4 · 95% CI -0.4 to 1.2
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.406 · Difference in least square means: 0.4 · 95% CI -0.5 to 1.2
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.191 · Differenec in least square means: 0.5 · 95% CI -0.3 to 1.3
SecondaryChange From Baseline in CGM Percent Time Spent in Level 1 Hyperglycemia (Time Above Target Range [TATR, >180-250 mg/dL]) and Level 2 Hyperglycemia (Time Very Above Target Range [TVATR >250 mg/dL])

All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay TATR \>180-250 mg/dL and TVATR \>250 mg/dL. The change was assessed as: Change = Baseline CGM parameter value + HbA1c strata (\<8.5% or ≥8.5%) + Methods of insulin administration (pump or MDI) + Week + Treatment + Treatment\*Week (repeated values over Week 8 and 16). The analysis was based on the MMRM.

Time frame:
Baseline (Day 1), Weeks 8 and 16
Reported as:
Least squares mean · precent time
Change From Baseline in CGM Percent Time Spent in Level 1 Hyperglycemia (Time Above Target Range [TATR, >180-250 mg/dL]) and Level 2 Hyperglycemia (Time Very Above Target Range [TVATR >250 mg/dL])
precent timeArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
TATR: Change at Week 80.4 ± 2.60-2.6 ± 2.75-1.9 ± 2.592.6 ± 2.57
TATR: Change at Week 162.0 ± 2.38-0.9 ± 2.53-1.3 ± 2.550.3 ± 2.37
TVATR: Change at Week 8-4.0 ± 2.20-3.8 ± 2.32-5.1 ± 2.19-0.1 ± 2.15
TVATR: Change at Week 16-0.4 ± 2.27-3.7 ± 2.41-1.5 ± 2.40-2.3 ± 2.24
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.278 · Difference in least square means: -2.9 · 95% CI -8.3 to 2.4
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.395 · Difference in least square means: -2.3 · 95% CI -7.5 to 3.0
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.394 · Difference in least square means: 2.2 · 95% CI -2.9 to 7.4
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.197 · Difference in least square means: -2.9 · 95% CI -7.3 to 1.6
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.154 · Difference in least square means: -3.3 · 95% CI -7.9 to 1.3
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.437 · Difference in least square means: -1.7 · 95% CI -6.0 to 2.6
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.906 · Difference in least square means: 0.3 · 95% CI -4.0 to 4.5
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.599 · Difference in least square means: -1.1 · 95% CI -5.2 to 3.0
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.055 · Difference in least square means: 3.9 · 95% CI -0.1 to 8.0
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.154 · Difference in least square means: -3.3 · 95% CI -7.9 to 1.3
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = 0.655 · Difference in least square means: -1.0 · 95% CI -5.7 to 3.6
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = 0.388 · Differenec in least square means: -1.9 · 95% CI -6.4 to 2.5
SecondaryEvent Rate With Sensor Glucose <70 mg/dL Lasting at Least 120 Minutes

All participants used a CGM device for glucose monitoring throughout the treatment. Data is reported for event rate (number of events per person-year). Number of events with sensor glucose \<70 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≥70 mg/dL for ≥15 minutes) was assessed. Percentages have been rounded off.

Time frame:
Weeks 8 and 16
Reported as:
Number · events per person-year
Event Rate With Sensor Glucose <70 mg/dL Lasting at Least 120 Minutes
events per person-yearArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Week 81.740.901.750.94
Week 160.382.031.612.29
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · Negative Binomial Regression Model · p = 0.271 · Adjusted risk ratio: 0.40 · 95% CI 0.08 to 2.05
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · Negative Binomial Regression Model · p = 0.518 · Adjusted risk ratio: 0.61 · 95% CI 0.14 to 2.70
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · Negative Binomial Regression Model · p = 0.247 · Adjusted risk ratio: 0.34 · 95% CI 0.06 to 2.09
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · Negative Binomial Regression Model · p = 0.265 · Adjusted risk ratio: 2.82 · 95% CI 0.46 to 17.47
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · Negative Binomial Regression Model · p = 0.582 · Adjusted risk ratio: 1.71 · 95% CI 0.26 to 11.39
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · Negative Binomial Regression Model · p = 0.428 · Adjusted risk ratio: 2.30 · 95% CI 0.29 to 18.00
SecondaryEvent Rate With Sensor Glucose >250 mg/dL Lasting at Least 120 Minutes

All participants used a CGM device for glucose monitoring throughout the treatment. Data are reported for event rates. Event=sensor glucose \>250 mg/dL lasting at least 120 minutes and without gaps \>30 minutes between consecutive CGM readings (event ends when glucose returns to ≤180 mg/dL for ≥15 minutes). Percentages have been rounded off.

Time frame:
Weeks 8 and 16
Reported as:
Number · events per person-year
Event Rate With Sensor Glucose >250 mg/dL Lasting at Least 120 Minutes
events per person-yearArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Week 819.8415.7319.3024.70
Week 1627.2317.4723.7219.85
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · Negative Binomial Regression Model · p = 0.925 · Adjusted risk ratio: 1.02 · 95% CI 0.66 to 1.58
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · Negative Binomial Regression Mode · p = 0.920 · Adjusted risk ratio: 1.02 · 95% CI 0.67 to 1.55
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · Negative Binomial Regression Model · p = 0.264 · Adjusted risk ratio: 1.25 · 95% CI 0.84 to 1.85
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · Negative Binomial Regression Model · p = 0.289 · Adjusted risk ratio: 0.80 · 95% CI 0.53 to 1.21
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · Negative Binomial Regression Model · p = 0.996 · Adjusted risk ratio: 1.00 · 95% CI 0.66 to 1.52
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · Negative Binomial Regression Model · p = 0.306 · Adjusted risk ratio: 0.82 · 95% CI 0.55 to 1.20
SecondaryNumber of Participants With TIR 70-180 mg/dL With ≥5% Points Improvement From Baseline

All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.

Time frame:
At Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TIR 70-180 mg/dL With ≥5% Points Improvement From Baseline
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Week 86995
Week 165436
SecondaryNumber of Participants With TIR 70-180 mg/dL With ≥10% Points Improvement From Baseline

All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.

Time frame:
At Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TIR 70-180 mg/dL With ≥10% Points Improvement From Baseline
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Week 82743
Week 163324
SecondaryNumber of Participants With TIR 70-180 mg/dL for >70% of the 14-day Collection Interval Around the Week 8 Visit and the 14-day Interval Prior to the Week 16 Visit

All participants used a CGM device for glucose monitoring throughout the treatment. TIR represents the percentage of time a participant's glucose levels stay within a target range of 70-180 mg/dL.

Time frame:
At Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TIR 70-180 mg/dL for >70% of the 14-day Collection Interval Around the Week 8 Visit and the 14-day Interval Prior to the Week 16 Visit
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Week 84655
Week 162542
SecondaryNumber of Participants With Time Below Range (TBR) <70 mg/dL for <4% of Each Day

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With Time Below Range (TBR) <70 mg/dL for <4% of Each Day
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline9777
Week 87338
Week 166346
SecondaryNumber of Participants With TBR <54 mg/dL for <1% of Each Day

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TBR <54 mg/dL for <1% of Each Day
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline106117
Week 84659
Week 168524
SecondaryNumber of Participants With Time Above Range (TAR) >180 mg/dL for <25% of Each Day

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With Time Above Range (TAR) >180 mg/dL for <25% of Each Day
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline1100
Week 80020
Week 160000
SecondaryNumber of Participants With TAR >250 mg/dL for <5% of Each Day

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TAR >250 mg/dL for <5% of Each Day
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline1110
Week 81021
Week 160001
SecondaryNumber of Participants With TBR <70 mg/dL for <4% Over the 14-day Collection Window

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TBR <70 mg/dL for <4% Over the 14-day Collection Window
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline23222021
Week 816161519
Week 1613131114
SecondaryNumber of Participants With TBR <54 mg/dL for <1% Over the 14-day Collection Window

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TBR <54 mg/dL for <1% Over the 14-day Collection Window
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline22232020
Week 815161719
Week 1616131115
SecondaryNumber of Participants With TAR >180 mg/dL for <25% Over the 14-day Collection Window

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TAR >180 mg/dL for <25% Over the 14-day Collection Window
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline3542
Week 84653
Week 162542
SecondaryNumber of Participants With TAR >250 mg/dL for <5% Over the 14-day Collection Window

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Count of participants · Participants
Number of Participants With TAR >250 mg/dL for <5% Over the 14-day Collection Window
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline6752
Week 86664
Week 163433
SecondaryPercent Change From Baseline in the Glycemic Risk Index

All participants used a CGM device for glucose monitoring throughout the treatment.

Time frame:
Baseline, Weeks 8 and 16
Reported as:
Mean · Percent change
Percent Change From Baseline in the Glycemic Risk Index
Percent changeArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 8-1.2 ± 31.951.1 ± 45.93-10.5 ± 31.798.0 ± 38.70
Change at Week 1613.5 ± 40.751.9 ± 32.7114.5 ± 26.196.6 ± 35.14
SecondaryPercent Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16
Time frame:
Baseline (Day 1), and Weeks 4, 8, 12, and 16
Reported as:
Least squares mean · Percent change in body weight
Percent Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16
Percent change in body weightArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Percent Change at Week 4-0.13 ± 0.451-2.31 ± 0.473-2.71 ± 0.461-2.47 ± 0.460
Percent Change at Week 8-0.41 ± 0.602-3.46 ± 0.629-4.81 ± 0.607-4.19 ± 0.621
Percent Change at Week 120.02 ± 0.716-3.12 ± 0.738-6.14 ± 0.718-5.29 ± 0.734
Percent Change at Week 160.29 ± 0.839-3.26 ± 0.865-6.43 ± 0.838-6.67 ± 0.861
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = <0.01 · Difference in least square means: -2.18 · 90% CI -3.05 to -1.32
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.01 · Difference in least square means: -2.58 · 90% CI -3.45 to -1.72
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.01 · Difference in least square means: -2.34 · 90% CI -3.21 to -1.48
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = <0.01 · Difference in least square means: -3.05 · 90% CI -4.34 to -1.76
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.01 · Difference in least square means: -4.39 · 90% CI -5.67 to -3.12
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.01 · Difference in least square means: -3.78 · 90% CI -5.07 to -2.49
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = <0.01 · Difference in least square means: -3.14 · 90% CI -4.72 to -1.55
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.01 · Difference in least square means: -6.16 · 90% CI -7.72 to -4.59
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.01 · Difference in least square means: -5.31 · 90% CI -6.89 to -3.73
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = <0.01 · Difference in least square means: -3.55 · 90% CI -5.45 to -1.65
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.01 · Difference in least square means: -6.72 · 90% CI -8.59 to -4.85
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.01 · Difference in least square means: -6.96 · 90% CI -8.85 to -5.06
SecondaryAbsolute Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16
Time frame:
Baseline (Day 1), and Weeks 4, 8, 12, and 16
Reported as:
Least squares mean · kilograms (kg)
Absolute Change From Baseline in Body Weight at Day 1 to Weeks 4, 8, 12, and 16
kilograms (kg)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Change at Week 4-0.07 ± 0.462-2.34 ± 0.484-2.59 ± 0.472-2.46 ± 0.471
Change at Week 8-0.36 ± 0.580-3.31 ± 0.608-4.51 ± 0.586-4.16 ± 0.598
Change at Week 120.00 ± 0.674-2.92 ± 0.696-5.73 ± 0.676-5.27 ± 0.690
Change at Week 160.39 ± 0.789-2.96 ± 0.814-5.95 ± 0.789-6.57 ± 0.808
Statistical analysis
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = <0.001 · Difference in least square means: -2.26 · 95% CI -3.34 to -1.18
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.001 · Difference in least square means: -2.52 · 95% CI -3.60 to -1.44
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.001 · Difference in least square means: -2.38 · 95% CI -3.46 to -1.31
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = <0.001 · Difference in least square means: -2.95 · 95% CI -4.43 to -1.47
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.001 · Difference in least square means: -4.15 · 95% CI -5.61 to -2.69
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.001 · Difference in least square means: -3.80 · 95% CI -5.28 to -2.33
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.001 · Difference in least square means: -2.92 · 95% CI -4.69 to -1.16
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.001 · Difference in least square means: -5.73 · 95% CI -7.47 to -3.98
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.001 · Difference in least square means: -5.28 · 95% CI -7.04 to -3.51
  • Arm 1: All Placebo vs Arm 2: CT-868 Titrated to 1.8 mg · MMRM · p = 0.002 · Difference in least square means: -3.34 · 95% CI -5.46 to -1.23
  • Arm 1: All Placebo vs Arm 3: CT-868 Titrated to 4.1 mg · MMRM · p = <0.001 · Difference in least square means: -6.34 · 95% CI -8.43 to -4.25
  • Arm 1: All Placebo vs Arm 4: CT-868 Titrated to 6.6 mg · MMRM · p = <0.001 · Difference in least square means: -6.96 · 95% CI -9.08 to -4.84
SecondaryPercentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16
Time frame:
At Week 16
Reported as:
Count of participants · Participants
Percentage of Participants Achieving ≥5%, ≥10%, ≥15%, and ≥20% Weight Loss at Week 16
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
≥5% Weight Loss261515
≥10% Weight Loss0213
≥15% Weight Loss0010
≥20% Weight Loss0000
SecondaryPercentage of Participants Experiencing 1 or More Level 1, 2, or 3 Hypoglycemia Events (Worst Severity)

Level 1 hypoglycemia: glucose between \<70-54 mg/dL; Level 2 hypoglycemia: glucose level between \<54 mg/dL; Level 3 hypoglycemia: These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma.

Time frame:
Postbaseline from Day 1 to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing 1 or More Level 1, 2, or 3 Hypoglycemia Events (Worst Severity)
percentage of participantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Level 1 Hypoglycemia20.713.35.95.6
Level 2 Hypoglycemia31.050.047.166.7
Level 3 Hypoglycemia0000
SecondaryEvent Rate of Level 2 Hypoglycemia Over the 2-Week Baseline Period and the 16-Week Treatment Period

The baseline period event rate was calculated as (the total number of events) / (14/365.25 \* number of patients). Baseline hypoglycemia events occurred within 14 days prior to first treatment start time (Day 1). The treatment period event rate was calculated as (the total number of events) / (sum of the person-time exposed to the study drug after randomization (in years)). Sum of the person-time exposed to the study drug after randomization is calculated as the time from first to last dose of study drug for all participants in the respective treatment arm.

Time frame:
Baseline Period (14 days before Day 1) and Treatment Period (up to 16 weeks)
Reported as:
Number · events per person-year
Event Rate of Level 2 Hypoglycemia Over the 2-Week Baseline Period and the 16-Week Treatment Period
events per person-yearArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Baseline Period7.209.577.6715.94
Treatment Period2.346.297.846.36
SecondaryNumber of Participants With Diabetic Ketoacidosis (DKA) Events

DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 milliequivalents per liter \[mEq/L\]), and accompanied by symptoms/signs per the anti-drug antibody (ADA) consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Number of Participants With Diabetic Ketoacidosis (DKA) Events
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Number of Participants With Diabetic Ketoacidosis (DKA) Events0000
SecondaryParticipants With DKA Events That Led to Hospitalization or Emergency Room Visits During the Study

DKA episode was defined as the presence of acidosis (blood pH \<7.3, serum bicarbonate levels \<18 mEq/L), and accompanied by symptoms/signs per the ADA consensus statement on diagnosis of DKA or if the DKA episode results in a hospital or emergency room stay.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Participants With DKA Events That Led to Hospitalization or Emergency Room Visits During the Study
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Participants With DKA Events That Led to Hospitalization or Emergency Room Visits During the Study0000
SecondaryNumber of Participants With Adverse Events (AEs) and Adverse Device Effects (ADEs) Over the Period of 16 Weeks

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An ADE was defined as an AE related to the medical device; in this study, the medical device is the pen device with which the study drug is administered. This included any event that was the result of incomplete user manual information or of incorrect use of the medical device.

Time frame:
Up to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Adverse Device Effects (ADEs) Over the Period of 16 Weeks
ParticipantsArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
AEs23263217
ADEs0000
SecondaryPlasma Drug Concentrations of CT-868 at the Weeks 2, 4, 6, 8, 12, and 16 Visits
Time frame:
At 24 hours post-dose on Weeks 2, 4, 6, 8, 12, and 16
Reported as:
Mean · micrograms per milliliter (µg/mL)
Plasma Drug Concentrations of CT-868 at the Weeks 2, 4, 6, 8, 12, and 16 Visits
micrograms per milliliter (µg/mL)Arm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
Week 262.7 ± 43.743.2 ± 26.771.6 ± 26.6
Week 474.1 ± 44.784.8 ± 42.0124 ± 85.6
Week 660.5 ± 48.9111 ± 67.2131 ± 88.0
Week 853.0 ± 44.0175 ± 96.4224 ± 111
Week 1269.2 ± 57.3189 ± 116440 ± 210
Week 1673.0 ± 71.5197 ± 116381 ± 240

Adverse events

Collected over From first dose of study drug until 30 days after the last dose of study drug (up to 20 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: All Placebo0/29 (0%)0/29 (0%)21/29 (72.4%)
Arm 2: CT-868 Titrated to 1.8 mg0/30 (0%)0/30 (0%)24/30 (80%)
Arm 3: CT-868 Titrated to 4.1 mg0/34 (0%)1/34 (2.9%)31/34 (91.2%)
Arm 4: CT-868 Titrated to 6.6 mg0/18 (0%)2/18 (11.1%)17/18 (94.4%)
Most frequent serious events
Most frequent serious events
EventArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
ConstipationGastrointestinal disorders0/290/300/341/18
HyponatraemiaMetabolism and nutrition disorders0/290/300/341/18
Infected biteInfections and infestations0/290/301/340/18
Most frequent other events
Showing 10 of 57
Most frequent other events
EventArm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mg
NauseaGastrointestinal disorders2/2913/3017/349/18
VomitingGastrointestinal disorders0/294/308/348/18
ConstipationGastrointestinal disorders3/296/3012/345/18
DiarrhoeaGastrointestinal disorders2/296/306/346/18
Gastrooesophageal reflux diseaseGastrointestinal disorders4/294/304/346/18
Decreased appetiteMetabolism and nutrition disorders4/296/306/346/18
DyspepsiaGastrointestinal disorders1/294/307/345/18
HypoglycaemiaMetabolism and nutrition disorders2/295/305/345/18
Injection site erythemaGeneral disorders0/292/303/344/18
Injection site pruritusGeneral disorders0/291/303/344/18

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mgTotal
Mean38.0 ± 12.5143.1 ± 13.7341.3 ± 11.7742.2 ± 14.8341.1 ± 13.20
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mgTotal
Female1819161770
Male118121041
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mgTotal
Hispanic or Latino357419
Not Hispanic or Latino2621212391
Unknown or Not Reported01001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mgTotal
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American11215
White27262525103
More than one race00000
Unknown or Not Reported00112
HbA1c Level at Baseline (Stratification Factor)
HbA1c Level at Baseline (Stratification Factor)(Participants)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mgTotal
HbA1c <8.5%2524232395
HbA1c ≥8.5%435416
Method of Insulin Administration
Method of Insulin Administration(Participants)Arm 1: All PlaceboArm 2: CT-868 Titrated to 1.8 mgArm 3: CT-868 Titrated to 4.1 mgArm 4: CT-868 Titrated to 6.6 mgTotal
Automated Insulin Delivery (AID)8981035
Non-AID (Pump)1299737
Multiple Daily Injections (MDI)99111039
08

Study locations

22 sites
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Headlands Research- AMCR
    Escondido, California 92025, United States
  • University of Colorado - Barbara Davis Center for Diabetes
    Aurora, Colorado 80045, United States
  • Denver Endocrinology Diabetes and Thyroid Center
    Englewood, Colorado 80113, United States
  • Advent Health
    Orlando, Florida 32804, United States
  • Orlando Health Science Clinic, LLC
    Orlando, Florida 32822, United States
  • Innovative Research Institute
    Port Charlotte, Florida 33952, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30309, United States
  • Rocky Mountain Clinical Research, LLC- Idaho Falls, Idaho
    Idaho Falls, Idaho 83404, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50266, United States
  • MedStar Health Research Institute - Washington Hospital Center
    Hyattsville, Maryland 20782, United States
  • University of North Carolina Health Sciences at MAHEC
    Asheville, North Carolina 28803, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27517, United States
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Texas Diabetes and Endocrinology, P.A
    Austin, Texas 78731, United States
  • Velocity Clinical Research - Dallas
    Dallas, Texas 75230, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Diabetes & Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • Consano Clinical Research
    Shavano Park, Texas 78231, United States
  • Texas Valley Clinical Research, LLC
    Weslaco, Texas 78596, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2025, 19 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's 19 months is above that.

Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.

Start moved once since we started tracking on Sep 25, 2026: Oct 2023 → Nov 2023, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Oct 2, 2023
StartActual
Nov 27, 2023was Oct 2023
Primary completionActual
Jul 7, 2025
CompletionActual
Jul 7, 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Start date
Oct 19, 2023→Nov 27, 2023
Oct 28, 2026
Primary completion
Jul 9, 2025→Jul 7, 2025
Oct 28, 2026
Study completion
Jul 9, 2025→Jul 7, 2025
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baselineNow Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16Time frame: at Day 1 to Week 16 → Baseline (Day 1) to Week 16
Oct 28, 2026
Documents
Secondary outcomes
3 edited, 27 added, 19 more
What changed in the outcomes
  • EditedTo assess the percentagePercentage of participants achievingParticipants Achieving HbA1c Target of <7.0%. at Week 16Time frame: at Week 16 → At Week 16
  • EditedTo assess the percentagePercentage of participants achievingParticipants Achieving HbA1c Target of ≤6.5%. at Week 16Time frame: at Week 16 → At Week 16
  • EditedTo assess the percentagePercentage of participants achievingParticipants Achieving HbA1c Target of <5.7%. at Week 16Time frame: at Week 16 → At Week 16
  • AddedPercent Change From Baseline in Body Weight at Week 16Time frame: Baseline (Day 1) to Week 16
  • AddedChange From Baseline in HbA1c (%) at Weeks 4, 8, and 12Time frame: Baseline (Day 1) to Weeks 4, 8, and 12
  • AddedChange From Baseline in Total Daily Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in Basal Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in Bolus Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedPercent Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedPercent Change From Baseline in Basal Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedPercent Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedPercent Change From Baseline in Body Weight-adjusted Total Daily Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedPercent Change From Baseline in Body Weight-adjusted Basal Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedPercent Change From Baseline in Body Weight-adjusted Bolus Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in Continuous Glucose Monitoring (CGM) Intraday Mean Sensor GlucoseTime frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in CGM Interday Mean Sensor GlucoseTime frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in Percentage of Time Spent in Range (TIR) 70-180 mg/dLTime frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in Percentage of TIR 70-140 mg/dLTime frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in CGM Percent Time Spent in Level 1 Hypoglycemia (Time Below Target Range [TBTR, <54-70 mg/dL]) and Level 2 Hypoglycemia (Time Very Below Target Range [TVBTR <54 mg/dL])Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedChange From Baseline in CGM Percent Time Spent in Level 1 Hyperglycemia (Time Above Target Range [TATR, >180-250 mg/dL]) and Level 2 Hyperglycemia (Time Very Above Target Range [TVATR >250 mg/dL])Time frame: Baseline (Day 1), Weeks 8 and 16
  • AddedEvent Rate With Sensor Glucose <70 mg/dL Lasting at Least 120 MinutesTime frame: Weeks 8 and 16
  • AddedEvent Rate With Sensor Glucose >250 mg/dL Lasting at Least 120 MinutesTime frame: Weeks 8 and 16
  • AddedNumber of Participants With TIR 70-180 mg/dL With ≥5% Points Improvement From BaselineTime frame: At Weeks 8 and 16
  • AddedNumber of Participants With TIR 70-180 mg/dL With ≥10% Points Improvement From BaselineTime frame: At Weeks 8 and 16
  • AddedNumber of Participants With TIR 70-180 mg/dL for >70% of the 14-day Collection Interval Around the Week 8 Visit and the 14-day Interval Prior to the Week 16 VisitTime frame: At Weeks 8 and 16
  • AddedNumber of Participants With Time Below Range (TBR) <70 mg/dL for <4% of Each DayTime frame: Baseline, Weeks 8 and 16
  • AddedNumber of Participants With TBR <54 mg/dL for <1% of Each DayTime frame: Baseline, Weeks 8 and 16
  • AddedNumber of Participants With Time Above Range (TAR) >180 mg/dL for <25% of Each DayTime frame: Baseline, Weeks 8 and 16
  • AddedNumber of Participants With TAR >250 mg/dL for <5% of Each DayTime frame: Baseline, Weeks 8 and 16
  • AddedNumber of Participants With TBR <70 mg/dL for <4% Over the 14-day Collection WindowTime frame: Baseline, Weeks 8 and 16
  • …and 19 more, on the record history on ClinicalTrials.gov ↗
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Start date Oct 19, 2023→Nov 27, 2023
    Primary completion Jul 9, 2025→Jul 7, 2025
    Study completion Jul 9, 2025→Jul 7, 2025
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baselineNow Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16Time frame: at Day 1 to Week 16 → Baseline (Day 1) to Week 16
    Secondary outcomes 3 edited, 27 added, 19 more
    What changed in the outcomes
    • EditedTo assess the percentagePercentage of participants achievingParticipants Achieving HbA1c Target of <7.0%. at Week 16Time frame: at Week 16 → At Week 16
    • EditedTo assess the percentagePercentage of participants achievingParticipants Achieving HbA1c Target of ≤6.5%. at Week 16Time frame: at Week 16 → At Week 16
    • EditedTo assess the percentagePercentage of participants achievingParticipants Achieving HbA1c Target of <5.7%. at Week 16Time frame: at Week 16 → At Week 16
    • AddedPercent Change From Baseline in Body Weight at Week 16Time frame: Baseline (Day 1) to Week 16
    • AddedChange From Baseline in HbA1c (%) at Weeks 4, 8, and 12Time frame: Baseline (Day 1) to Weeks 4, 8, and 12
    • AddedChange From Baseline in Total Daily Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in Basal Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in Bolus Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedPercent Change From Baseline in Total Daily Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedPercent Change From Baseline in Basal Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedPercent Change From Baseline in Bolus Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedPercent Change From Baseline in Body Weight-adjusted Total Daily Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedPercent Change From Baseline in Body Weight-adjusted Basal Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedPercent Change From Baseline in Body Weight-adjusted Bolus Insulin Dose at Weeks 8 and 16Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in Continuous Glucose Monitoring (CGM) Intraday Mean Sensor GlucoseTime frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in CGM Interday Mean Sensor GlucoseTime frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in Percentage of Time Spent in Range (TIR) 70-180 mg/dLTime frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in Percentage of TIR 70-140 mg/dLTime frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in CGM Percent Time Spent in Level 1 Hypoglycemia (Time Below Target Range [TBTR, <54-70 mg/dL]) and Level 2 Hypoglycemia (Time Very Below Target Range [TVBTR <54 mg/dL])Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedChange From Baseline in CGM Percent Time Spent in Level 1 Hyperglycemia (Time Above Target Range [TATR, >180-250 mg/dL]) and Level 2 Hyperglycemia (Time Very Above Target Range [TVATR >250 mg/dL])Time frame: Baseline (Day 1), Weeks 8 and 16
    • AddedEvent Rate With Sensor Glucose <70 mg/dL Lasting at Least 120 MinutesTime frame: Weeks 8 and 16
    • AddedEvent Rate With Sensor Glucose >250 mg/dL Lasting at Least 120 MinutesTime frame: Weeks 8 and 16
    • AddedNumber of Participants With TIR 70-180 mg/dL With ≥5% Points Improvement From BaselineTime frame: At Weeks 8 and 16
    • AddedNumber of Participants With TIR 70-180 mg/dL With ≥10% Points Improvement From BaselineTime frame: At Weeks 8 and 16
    • AddedNumber of Participants With TIR 70-180 mg/dL for >70% of the 14-day Collection Interval Around the Week 8 Visit and the 14-day Interval Prior to the Week 16 VisitTime frame: At Weeks 8 and 16
    • AddedNumber of Participants With Time Below Range (TBR) <70 mg/dL for <4% of Each DayTime frame: Baseline, Weeks 8 and 16
    • AddedNumber of Participants With TBR <54 mg/dL for <1% of Each DayTime frame: Baseline, Weeks 8 and 16
    • AddedNumber of Participants With Time Above Range (TAR) >180 mg/dL for <25% of Each DayTime frame: Baseline, Weeks 8 and 16
    • AddedNumber of Participants With TAR >250 mg/dL for <5% of Each DayTime frame: Baseline, Weeks 8 and 16
    • AddedNumber of Participants With TBR <70 mg/dL for <4% Over the 14-day Collection WindowTime frame: Baseline, Weeks 8 and 16
    • …and 19 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06062069
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Nov 27, 2023
Primary completion
Jul 7, 2025
Completion
Jul 7, 2025
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Clinical Trials
study director · Carmot Therapeutics, Inc., a member of the Roche Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CT-868

Start the discussion